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Abstract. Background/Aim: Nitric oxide (NO) pathway
plays a major role in the development and advancement of
inflammation. We aimed to design a study and investigate its
feasibility to show the changes of L-arginine, asymmetric
dimethylarginine (ADMA) and symmetric dimethylarginine
(SDMA), which are important regulators of the NO pathway.
Patients and Methods: Concentrations of L-arginine, ADMA
and SDMA were measured by liquid chromatography-
tandem mass spectrometry. Seventeen septic survival patients
were enrolled and blood samples were obtained on the first,
third and fifth day after the diagnosis of sepsis. Sixteen non-
septic matched controls were recruited. Results: ADMA
levels on admission correlated well with sequential organ
failure assessment (SOFA) score. During the follow-up, L-
arginine/ADMA ratio increased significantly from day 1 to
day 3 (p=0.005), then decreased from day 3 to day 5
(p=0.023). Conclusion: This study design seems feasible to
investigate changes of L-Arginine, ADMA and SDMA in
sepsis survival patients.
Sepsis syndrome remains one of the most challenging
healthcare issues worldwide. The prominently high mortality
rate (approximately 30%) and costs of care (22,000
USD/case) makes it a remarkable disease (1). Septic shock
belongs to the leading causes of death in intensive-care units
(ICU), even nowadays (2). Early diagnosis and goal-directed
therapy are essential for favorable outcome (3). Beside the
clinical signs and symptoms, laboratory parameters are
essential in proper decision-making. Monitoring the septic
process is an essential part of successful therapy; therefore,
biomarkers with predictive capacity would be of utmost
importance, which are unfortunately not available in current
management of sepsis.
Nitric oxide (NO) is a crucial mediator in the
inflammatory activation process (4). During sepsis, NO
overproduction plays a major role in the development of
hemodynamic instability and organ failure. Due to
uncoupling of nitric oxide synthase (NOS), excessive
production of free radicals, particularly peroxynitrite, leads
to oxidative cell injury. Previous studies have shown that
NOS inhibitors like endogenous dimethylarginines take
considerable role in sepsis by modulating NO related
biochemical pathways (5).
Dimethylarginines are produced as a result of protein
degradation; methylation occurs by the protein arginine
methyltransferase enzyme type 1 and 2 (PRMT-1, PRMT-2).
Asymmetric dimethylarginine (ADMA) is produced by PRMT
1, while symmetric dimethylarginine (SDMA) by PMRT-2 (6,
7). SDMA levels are mainly modulated by urinary excretion;
however, certain metabolic routes have been found to
correspond with its regulation (8). Only 20% of ADMA is
secreted into urine and it – but not SDMA – is mainly
metabolized by dimethylarginine dimethylaminohydrolase
enzyme (DDAH). DDAH-1 is expressed in neuronal tissues,
while DDAH-2 is mainly found in endothelial cells.
Expression and function of DDAH is impaired by increased
glucose, hypercholesterinemia, hyperhomocysteinemia and
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inflammatory milieu (6, 9). Loss of efficiency of DDAH is
directly proportional to the severity of oxidative stress (10).
L-arginine is converted by endothelial nitric oxide synthase
(eNOS) to L-citrulline and NO. The crucial role of NO in
vascular homeostasis and in organ perfusion is well known.
Several factors are capable of impairing the beneficial effects
of NO. One of them is ADMA, which is an endogenous
competitive inhibitor of NOS. Case-control studies have
found elevated ADMA concentrations among patients with
classic cardiovascular risk factors (e.g. smoking,
hypertension, obesity, diabetes mellitus, etc.) (5, 6). Elevated
ADMA levels reduce vascular reactivity and increase
peripheral resistance irrespective of disease-related or
externally administered drugs influencing vascular response
(11, 12). Due to its biological functions, ADMA is considered
to be a novel cardiovascular (CV) risk factor. In the case of
CV diseases, the clinical significance of ADMA is very well
outlined. ADMA has been proven to play a prominent role in
atherogenesis; furthermore, it is a marker of endothelial
dysfunction. Based on large cohort studies, ADMA is capable
of predicting end-points of CV diseases independently (13-
18). Until recently, SDMA was considered a functionally
inactive isomer of ADMA; however, nowadays, it is found to
compete with L-arginine in the reaction with NOS. Therefore,
it can decrease NO indirectly. Moreover, overproduction of
both ADMA and SDMA were found to increase the formation
of reactive oxygen species (11, 19).
This pilot study aimed to test the feasibility of the study
design in monitoring the changes of L-arginine and
dimethylarginines in early sepsis. Furthermore, the Authors
aimed to identify a possible alteration pattern of the
mentioned biomarkers in sepsis survival patients, and
describe their informational value on disease severity and
sepsis-related organ dysfunctions.
Patients and Methods
Study design. The present study was performed at our
multidisciplinary adult ICU from January 2015 to April 2015.
Severe septic patients were enrolled and followed- up for 5 days.
Severe sepsis was defined as recommended by the current
consensus and guidelines (20, 21). Inclusion criteria were survival
of ICU stay, sepsis-induced organ dysfunction, hypoperfusion
abnormalities or hypotension and procalcitonin levels of >2 ng/ml.
The first sample was obtained within 24 h after clinical diagnosis
and further samples were taken on the 3rd and 5th days,
respectively. Sequential organ failure assessment (SOFA) scoring
system was used to describe organ dysfunctions (22).
The study protocol was approved by the Regional Ethics
Committee of University of Pécs (permission No.: 4327.316-
2900/KK15/2011.) in accordance with the 2008 Helsinki declaration.
Informed written consent was obtained from every patient.
Exclusion criteria were history of chronic kidney disease, acute
myocardial infarction (AMI), stroke, likelihood risk of death due to
primary disease and withdrawal of consent.
Age- and gender-matched patients with similar medical history
were recruited as control group. Only one sample was obtained from
the control patients.
Sampling and obtaining routine laboratory and clinical data. Daily
routine parameters (white blood cells (WBC), high-sensitivity C-
reactive protein (hs-CRP), procalcitonin (PCT), lactate
dehydrogenase (LDH), creatinine, urea, etc.) were measured in our
university clinical laboratory on automated analyzers by
manufacturer’s protocol (Cobas 8000; Roche Diagnostics GmbH,
Mannheim, Germany). Clinical data, like organ dysfunction
parameters (blood pressure, urine output, drugs, etc.), were
registered daily. For the assessment of disease severity and mortality
prediction, the simplified acute physiology score II (SAPS II), the
acute physiology and chronic health evaluation II (APACHE II) and
the SOFA scores were calculated. Patients surviving ICU were
considered to be survivors.
Blood samples were taken using 3.8% sodium-citrate BD
Vacutainer® Blood Collection tubes (Becton Dickinson, Franklin
Lakes, NJ, USA) both from septic and control patients besides the
daily blood collection for routine laboratory tests. After
centrifugation (1,500 × g, 10 min) plasma was collected and stored
at –70˚C until analysis.
Measurement of L-arginine and dimethylarginines. After sample
preparation, L-arginine, ADMA and SDMA levels were determined
by liquid chromatography-tandem mass spectrometry method
described by Martens-Lobenhoffer et al. (23). Minor modifications
were implemented to transfer the method to our Dionex Ultimate
3000 HPLC/Thermo Q Exactive setup (Thermo Fisher Scientific,
Waltham, MA, USA). Target substances were separated using a
Kinetex HILIC column (product no.: 00D-4461-AN; Phenomenex,
Torrance, CA, USA). Data obtained in MS2 mode were extracted by
pseudo-MRM method using the “Xcalibur 2.2 Qual Browser”
evaluation software (Thermo Fisher Scientific).
L-arginine monohydrochloride (product no.: A5131; Sigma
Aldrich, Saint Louis, MO, USA), NG,NG’-Dimethyl-L-arginine di(p-
hydroxyazobenzene-p’-sulfonate) (product no.: D0390; Sigma
Aldrich) and NG,NG Dimethylarginine dihydrochloride (product no.:
D4268; Sigma Aldrich) standards were used for calibration.
The quantitation range was 0.073-37.5 μM for ADMA and
SDMA and 1.172-150 μM for L-arginine. The calibration models
used in these ranges were non-linear regarding that the ion trap
instruments have narrow linear quantitative range. The regression
coefficient was R2>0.995 and the precision was lower than 10%
relative standard deviation (RSD) for all compounds in case of the
calibrations. The accuracy was ± =15% for the quality control (QC)
samples (spiked plasma).
Statistical analysis. Statistical analysis was performed by IBM SPSS
Statistics for Windows Version 22 (IBM Corp, Armonk, NY, USA).
Sample normality was checked by Shapiro-Wilk test. In the case of
variables showing normal distribution (ADMA), independent
sample t-test was used to compare two groups and one-way ANOVA
was performed to compare more than two groups. Data acquired
during the follow-up study were analyzed with repeated measures
ANOVA tests.
Non-parametric tests were used to compare non-normally
distributed variables (L-arginine, SDMA). For comparison of our
groups, Mann-Whitney U-test (two groups) or Kruskal-Wallis test
in vivo 30: 663-670 (2016)
664
(more than two groups) were carried out, while differences during
the follow-up were investigated by Friedman’s two-way ANOVA.
To reveal correlations, Spearman’s Rank Order Test was used. All
p-values lower than 0.05 were considered as statistically
significant. Continuous variables are presented as medians with
quartiles (25-75%).
Results
Clinical characteristics and disease outcome of participants.
In the present study, 17 severe septic patients and 16 age-,
gender- and medical history-matched control individuals
were enrolled. Demographic data are represented in Table I.
Among 17 septic patients, 12 suffered from septic shock, the
remaining 5 patients developed sepsis-induced organ
dysfunctions. In four cases of sepsis, no microbes were
identified, 2/2 patients suffered from isolated Gram-positive
or Gram-negative bacteria, only one patient had fungal
infection and mixed microbial infections were identified in
eight patients. Clinical characteristics of involved patients
are shown in Table II.
The baseline of controls and follow-ups of septic patients
ADMA, SDMA, L-arginine, ADMA/SDMA ratio and L-
arginine/ ADMA ratio are shown in Figures 1 and 2.
Significant biochemical parameters are shown in Table III.
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Table I. Demographic data of the involved patients.
                                                        Control group          Septic patients
Number of patients                                 16                            17
Mean age, years (±SD)                         61 (13)                    66 (15)
Male, n (%)                                             9 (56)                      8 (47)
Hypertension, n (%)                              13 (81)                    14 (82)
Pulmonary disease, n (%)                       6 (38)                      8 (47)
Diabetes Type 2, n (%)                           4 (24)                      4 (24)
Table II. Clinical characteristics of septic patients. Median data and
IQR are presented.
                                                                            Septic patients
Type of admission                                                       
   surgical, n (%)                                                    11 (65)
   non-surgical, n (%)                                              6 (35)
Length of ICU stay, days (IQR)                             7 (3-8)
SOFA score, (IQR)                                                  7 (5-9)
SAPS II score, (IQR)                                             39 (34-51)
APACHE II score, (IQR)                                      16 (12-23)
ICU, Intensive care unit; SOFA, sepsis-related organ failure assessment;
SAPS, simplified acute physiology score; APACHE, acute physiology
and chronic health evaluation; IQR, interquartile range.
Figure 1. Monitoring of endogenous dimethylarginines (A, B) and 
L-arginine (C) in sepsis. ADMA, asymmetric dimethylarginine; SDMA,
symmetric dimethylarginine; ns, non-significant.
Both hs-CRP and PCT showed decreasing tendency during
the follow-up period. Hs-CRP and PCT levels decreased
significantly from day 1 to day 3 (p<0.005), further decrease
was found from day 3 to day 5 (p<0.005).
ADMA, survival and disease severity. There were no
significant differences in ADMA concentrations between
controls and septic patients on the first follow-up day.
However, ADMA was significantly higher in septic patients
on day 3 (p=0.001) and day 5 (p=0.003) compared to
controls. During the follow-up, ADMA increased
significantly from day 1 to day 3 (p=0.003); afterwards, on
day 5, ADMA decreased, but remained significantly higher
than on day 1 (p=0.027). Patients suffering from more than
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Figure 2. L-arginine/ADMA ratio (A) and ADMA/SDMA ratio (B) in sepsis. ADMA, asymmetric dimethylarginine; SDMA, symmetric
dimethylarginine; ns, non-significant.
Table III. Baseline biochemical parameters of controls and follow-ups of septic patients. 
                                                  Control group                                                                               Septic patients
                                                                                                           Day 1                                           Day 3                                            Day 5
WBC count                                       7.64                                          12.90                                            11.70                                             10.67
(G/l)                                             (5.99-8.23)                               (9.22-17.83)                                (8.77-14.37)                                 (8.77-15.68)
Neutrophil count                               4.78                                          11.32                                            10.75                                              9.27
(G/l)                                             (3.37-5.83)                               (7.39-16.51)                                (7.59-12.61)                                 (6.32-13.02)
Lactate                                                 –                                                2                                                   1                                                 1.25
(mmol/l)                                                                                           (1.2-2.6)                                     (0.725-1.4)                                 (0.875-1.375)
Total protein                                      72.3                                           46.8                                               49                                               48.55
(g/l)                                              (68.9-75.5)                                (42.5-50.3)                                    (45.1-52)                                     (43.3-52.3)
LDH                                                   370                                            548                                               566                                                423
(U/l)                                              (348-406)                                  (379-702)                                     (423-690)                                     (362-535)
hs-CRP                                              1.91                                         182.00                                           152.8                                             67.45
(mg/l)                                         (0.6975-4.74)                          (124.40-260.61)                           (106.55-210.4)                             (36.79-129.28)
PCT                                                      –                                              4.49                                              1.74                                               1.01
(ng/ml)                                                                                          (2.39-11.17)                                 (0.987-5.78)                                  (0.52-2.05)
Urea                                                   5.20                                           7.88                                              9.22                                               10.8
(mmol/l)                                      (4.50-5.975)                              (6.40-12.27)                                (7.03-15.23)                                (6.825-18.22)
Creatinine                                         63.00                                        104.00                                            103                                                 81
(μmol/l)                                      (56.75-72.25)                           (76.00-131.00)                                  (55-149)                                      (52-151.2)
WBC, White blood cells; LDH, lactate dehydrogenase; hs-CRP, high-sensitivity C-reactive protein; PCT, procalcitonin. Data are presented as median
and interquartile range (IQR). Lactate and PCT were not measured in controls.
three organ failures had significantly higher ADMA
concentrations compared to patients with less than three
organ failures (0.573 vs. 0.425 μmol/l, p=0.018). Regarding
the first follow-up day, higher ADMA concentrations were
found in patients with SOFA >10 compared to SOFA <10
patients (0.542 vs. 0.307 μmol/l, p=0.004). ADMA levels
correlated well with SOFA scores (0.587, p=0.013).
SDMA and acute kidney injury. During the follow-up period,
septic patients had significantly higher SDMA concentrations
than controls (p<0.001). No significant changes were found
between septic patients during the follow-up period. Patients
who developed acute kidney injury during sepsis had
significantly higher SDMA concentrations compared to
patients without kidney injury (0.81 vs. 0.43 μmol/l,
p<0.001). A strong correlation was found between SDMA
and urea (0.732, p<0.001) and SDMA and creatinine levels,
respectively (0.793, p<0.001).
L-arginine. On the first follow-up day, lower L-arginine
concentrations were measured in septic patients compared to
controls (p<0.001). However, a significant elevation was found
from day 1 to day 3 in sepsis, (p<0.001); afterwards, L-arginine
levels decreased significantly from day 3 to day 5 (p=0.004).
L-arginine/ADMA ratio. Control patients had significantly
higher L-arginine/ADMA ratio than septic patients on day 1
(p<0.001); afterwards, the ratio showed an increasing non-
significant tendency. Finally, on day 5, the ratio decreased
and remained significantly lower compared to controls
(p=0.007). We found significantly increased L-
arginine/ADMA ratio from day 1 to day 3 (p=0.005).
Moreover, on day 5, L-arginine/ADMA ratio decreased
significantly compared to day 3 (p=0.023). Patients with
sepsis-induced hypoperfusion showed significantly elevated
L-arginine/ADMA ratios (p=0.015).
ADMA/SDMA ratio. Control patients had significantly higher
ADMA/SDMA ratio than septic patients on day 1 (p<0.001).
Regarding the septic patients, significantly increased
ADMA/SDMA ratio was found from day 1 to day 3 (p=0.015);
afterwards, the ratio levels decreased significantly from day 3
to day 5 (p=0.036).
Discussion
Several studies have investigated plasma dimethylarginine
levels in sepsis. However, in some studies, more than 
24 h elapsed between sepsis diagnosis and sample collection.
Consequently, initial stage of sepsis was missed (24), while
others were only limited to two samples (19, 25-27). Only two
relevant studies have investigated L-arginine, ADMA and
SDMA levels together. One of these used an inaccurate
sampling protocol, taking blood samples at the onset of sepsis
and between the 2nd and 4th day (25). The other study missed
to report the changes of L-arginine and L-arginine/ADMA
ratio, thereby lacking the information of NO bioavailability
(28). The precise regulation of NO system is essential to
survive sepsis. Insufficient production of NO impairs the
activity of antimicrobial system. However, uncontrolled NO
production can lead to uncontrollable hypotension and
massive oxidative stress, that can result in organ failure and
death (5). These findings delineate the effects of L-arginine
and dimethylarginines on NO system during sepsis. ADMA
levels are considered to be associated with sepsis survival due
to their significant role in vascular reactivity, microcirculation
and organ perfusion (19, 25, 26). This association was
confirmed even in this few-patient population by revealing
significant correlation between ADMA levels and SOFA score
measured and calculated on day 1. Regarding organ
dysfunctions, SDMA seems to be an early marker of acute
kidney injury, which can be explained by its urinary excretion
(6, 28). The initially decreased L-arginine levels shown in
Figure 1 are in line with literature and can be explained by
massive catabolic state and reduced, de novo L-arginine
production (29). The causes of increased L-arginine levels
during the course of sepsis are controversial. As shown in
Figure 1, blood levels of L-arginine and ADMA were elevated
significantly from day 1 to day 3, which agrees with the so
called “L-arginine paradox”. Namely, ADMA levels are high
enough to impair the function of eNOS enzyme making it
incapable of converting L-arginine to NO, despite the
sufficient amount of L-arginine (29-32). Subsequently, both L-
arginine and ADMA show non-significant decreasing
tendencies but remain, however, still significantly higher than
on the onset of sepsis. This can be explained by the efficient
treatment indicated by the decreasing tendencies of hs-CRP
and PCT and high survival rate. L-arginine/ADMA ratio is
considered as an indicator of NO bioavailability. The crucial
importance of NO levels in sepsis has been demonstrated in
several studies (25, 28-30, 33). Regarding the onset of sepsis,
we found decreased L-arginine/ADMA ratio, which can
indicate reduced endothelial NO production due to reduced
availability of L-arginine to NOS (31, 32). The elevation of
L-arginine/ADMA ratio experienced from day 1 to day 3 can
be once again attributed to the “L-arginine paradox”.
Interestingly, L-arginine/ADMA ratio calculated on day 1 to
day 5 showed no significant differences. The results provided
by Brenner et al. showed similar trends in changes of 
L-arginine/ADMA ratio but with a 2-day right shift in time
(33). Due to the high survival rate and decreasing tendencies
of PCT and hs-CRP, L-arginine/ADMA ratio shown in Figure
2 could denote a survival pattern. In addition, ADMA/SDMA
ratio shows an increasing trend from day 1 to day 3 and from
day 3 to day 5, which is very similar to the time course of
survivor patients demonstrated by Iapichino et al. (28).
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Conclusion
This study design seems to be capable to investigate the NO
pathway in sepsis through the changes of L-arginine and
dimethylarginines. Measuring the levels and interpreting the
results by these molecules together might provide valuable
information regarding the ongoing septic process. Besides
prediction of sepsis outcome, L-arginine/ADMA ratio could
be a reliable indicator of successful therapy by providing
information on NO bioavailability. Furthermore,
dimethylarginines could be new and promising target
molecules in sepsis treatment.
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